Transaction DateRecipientSharesTypePriceValue
29th January 2021Anirvan Ghosh250,000Grant/award etc.$0.00
16th December 2020Nathaniel E David1,700,000Open or private sale$5.24$8,908,000.00
13th September 2020Anirvan Ghosh300,000Grant/award etc.$0.00
13th September 2020Lynne Marie Sullivan240,000Grant/award etc.$0.00
13th September 2020Jamie Dananberg240,000Grant/award etc.$0.00
13th September 2020Alexander Azoy135,000Grant/award etc.$0.00
9th September 2020Ii Robert C. Goeltz5,000Open or private purchase$21.57$107,848.50
22nd June 2020Ii Robert C. Goeltz2,483Payment by withholding$9.67$24,010.61
22nd June 2020Jamie Dananberg2,483Payment by withholding$9.67$24,010.61
22nd June 2020Nathaniel E David2,483Payment by withholding$9.67$24,010.61
Unity Biotechnology
Unity Biotechnology logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.

Unity Biotechnology, Inc. operates as a biotechnology company. The company was founded by Nathaniel David, Jan van Deursen, Judith Campisi and Daohong Zhou in March 2009 and is headquartered in Brisbane, CA.

Ticker: UBX
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1463361
Employees: 98
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Cash at Carrying Value: $40 M (0%)
Marketable Securities, Current: $72 M (-14%)
Assets, Current: $124 M (-4%)
Property, Plant and Equipment, Net: $14 M (-14%)
Other Assets, Noncurrent: $598 Th (-4%)
Assets: $165 M (8%)
Accounts Payable, Current: $4 M (-23%)
Accrued Liabilities, Current: $6 M (25%)
Liabilities, Current: $16 M (-8%)
Liabilities: $52 M (71%)
Common Stock, Value, Issued: $5 Th (0%)
Common Stock, Shares, Issued: $52 M (9%)
Additional Paid in Capital, Common Stock: $405 M (10%)
Retained Earnings (Accumulated Deficit): $292 M (0%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $232 Th (157%)
Stockholders' Equity (Parent): $112 M (0%)
Liabilities and Equity: $165 M (8%)
Research and Development: $16 M (-54%)
General and Administrative Expenses: $6 M (-48%)
Operating Income/Loss: $23 M (-53%)